Form 4: ADAR1 Capital Management Increases Stake in Pieris Pharmaceuticals

ADAR1 Capital Management, a significant shareholder in Pieris Pharmaceuticals, has reported further acquisitions of common stock.

Summary

• ADAR1 Capital Management, LLC, through related entities, acquired additional shares of Pieris Pharmaceuticals (PIRS) common stock.
• On August 9, 2024, 3,000 shares were purchased at a price of $14.8929 per share.
• On August 12, 2024, 2,243 shares were purchased at $15.8824 per share by ADAR1 Partners.
• An additional 757 shares were purchased on August 12, 2024, at $15.8824 per share by Spearhead Insurance Solutions IDF, LLC Series ADAR1.
• Following these transactions, ADAR1 Capital Management's indirect beneficial ownership totals 129,574 shares through ADAR1 Partners and 15,067 shares through Spearhead Insurance Solutions IDF, LLC Series ADAR1.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Increased buying by a major shareholder is generally a good sign, but it's a routine disclosure.

Positives

• Increased investment by a major shareholder could signal confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures, but increased buying activity by significant shareholders is often viewed positively by the market.

Stakeholder Impact

• The increased stake by ADAR1 Capital Management could be viewed positively by shareholders.

Key Dates